
Supernus Pharmaceuticals Inc
NASDAQ:SUPN

Intrinsic Value
The intrinsic value of one
SUPN
stock under the Base Case scenario is
43.8
USD.
Compared to the current market price of 30.29 USD,
Supernus Pharmaceuticals Inc
is
Undervalued by 31%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Supernus Pharmaceuticals Inc
Fundamental Analysis


Revenue & Expenses Breakdown
Supernus Pharmaceuticals Inc
Balance Sheet Decomposition
Supernus Pharmaceuticals Inc
Current Assets | 686.1m |
Cash & Short-Term Investments | 453.6m |
Receivables | 142.1m |
Other Current Assets | 90.4m |
Non-Current Assets | 682m |
PP&E | 36m |
Intangibles | 638.9m |
Other Non-Current Assets | 7.1m |
Free Cash Flow Analysis
Supernus Pharmaceuticals Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Supernus Pharmaceuticals Inc
Revenue
|
661.8m
USD
|
Cost of Revenue
|
-69m
USD
|
Gross Profit
|
592.8m
USD
|
Operating Expenses
|
-502.2m
USD
|
Operating Income
|
90.6m
USD
|
Other Expenses
|
-16.7m
USD
|
Net Income
|
73.9m
USD
|
SUPN Profitability Score
Profitability Due Diligence
Supernus Pharmaceuticals Inc's profitability score is 53/100. The higher the profitability score, the more profitable the company is.

Score
Supernus Pharmaceuticals Inc's profitability score is 53/100. The higher the profitability score, the more profitable the company is.
SUPN Solvency Score
Solvency Due Diligence
Supernus Pharmaceuticals Inc's solvency score is 76/100. The higher the solvency score, the more solvent the company is.

Score
Supernus Pharmaceuticals Inc's solvency score is 76/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SUPN Price Targets Summary
Supernus Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
SUPN
is 39.58 USD
with a low forecast of 36.36 USD and a high forecast of 46.2 USD.
Dividends
Current shareholder yield for SUPN is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
SUPN
stock under the Base Case scenario is
43.8
USD.
Compared to the current market price of 30.29 USD,
Supernus Pharmaceuticals Inc
is
Undervalued by 31%.